Busulfan: all 322 studies that test it

Page 2 of 4. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma PatientsCompletedNCT00948090Phase 2Results posted
• Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic MalignanciesCompletedNCT00943319Phase 1/2Results posted
• Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00941720Phase 2Results posted
• Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk MalignanciesCompletedNCT00857389Phase 2Results posted
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and ThymoglobulinCompletedNCT00822770Phase 1/2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• Double Cord Blood Transplant for Patients With Malignant and Non-malignant DisordersTerminatedNCT00801931Phase 1/2Results posted
• Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideCompletedNCT00800839Phase 2Results posted
• Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by ChemotherapyCompletedNCT00796562Phase 2Results posted
• Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic MalignanciesCompletedNCT00795132Phase 2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)TerminatedNCT00684255Phase 1Results posted
• Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of MetabolismTerminatedNCT00668564Phase 2Results posted
• Reduced Intensity AlloTransplant For OsteopetrosisTerminatedNCT00638820Phase 2Results posted
• Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00630565Phase 2/3Results posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCIDCompletedNCT00598481Phase 2Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological DiseasesCompletedNCT00582894Not applicableResults posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous DiseaseCompletedNCT00578643Phase 2Results posted
• Bone Marrow Transplantation, Hemoglobinopathies, SCALLOPTerminatedNCT00578344Not applicableResults posted
• Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLOTerminatedNCT00578292Not applicableResults posted
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
• Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00553202Phase 2Results posted
• AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & DisordersCompletedNCT00547196Not applicableResults posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid CancerTerminatedNCT00540995Phase 1/2Results posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RCompletedNCT00534469Phase 2Results posted
• Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic CancerCompletedNCT00534430Phase 2Results posted
• Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell SupportCompletedNCT00506857Phase 1/2Results posted
• Busulfan and Fludarabine in Patients With AML and MDSCompletedNCT00502905Phase 2Results posted
• Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsTerminatedNCT00499889Phase 2Results posted
• Phase II Trial of Pentostatin and Targeted BusulfanCompletedNCT00496340Phase 2Results posted
• Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis BullosaTerminatedNCT00478244Not applicableResults posted
• Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic SyndromeCompletedNCT00475020Phase 2Results posted
• IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00469144Phase 3Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00445744Not applicableResults posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell TransplantationTerminatedNCT00363467Not applicableResults posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaCompletedNCT00357565Phase 2Results posted
• Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's TumorsCompletedNCT00357396Phase 2Results posted
• Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaCompletedNCT00322101Phase 3Results posted
• Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's LymphomaCompletedNCT00265889Phase 2Results posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's LymphomaCompletedNCT00238433Phase 2Results posted
• Stem Cell Transplantation for HurlerCompletedNCT00176917Phase 2Results posted
• Stem Cell Transplant for Inborn Errors of MetabolismCompletedNCT00176904Phase 2/3Results posted
• Stem Cell Transplant for Bone Marrow Failure SyndromesCompletedNCT00176878Phase 2/3Results posted
• Stem Cell Transplant for HemoglobinopathyCompletedNCT00176852Phase 2/3Results posted
• Stem Cell Transplantation for Hematological MalignanciesTerminatedNCT00176839Phase 2/3Results posted
• T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersTerminatedNCT00176826Phase 2/3Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma PatientsTerminatedNCT00113919Phase 1/2Results posted
• Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete RemissionCompletedNCT00070135Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00054327Phase 2Results posted
• Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaCompletedNCT00004088Phase 2Results posted
• Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00003875Phase 2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerCompletedNCT00003199Phase 2Results posted
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AMLTerminatedNCT05569512Phase 1
• G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCTStatus unknownNCT05453552Phase 2/3
• Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)CompletedNCT04942730Phase 2
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
• A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
• Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
• A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingNCT04217278Phase 2/3
• Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell TransplantationActive, not recruitingNCT04098393Phase 1
• Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingNCT03910452Early Phase 1
• Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
• Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)CompletedNCT03792815Phase 2
• Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCIDCompletedNCT03765632Phase 1/2
• BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCTStatus unknownNCT03733327Phase 2/3
• A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedNCT03653247Phase 1/2
• Conditioning SCID Infants Diagnosed EarlyActive, not recruitingNCT03619551Phase 2
• Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownNCT03602131Phase 2
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaWithdrawnNCT03515707Phase 2
• Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownNCT03385096Phase 2/3
• Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic LeukemiaStatus unknownNCT03339700Phase 2
• Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined ImmunodeficiencyStatus unknownNCT03315078Phase 1/2
• Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03247088Phase 1/2
• Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorStatus unknownNCT03171831Phase 4
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownNCT03151876Phase 2
• Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesActive, not recruitingNCT03121014Phase 2
• Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaWithdrawnNCT02961816Phase 2

← Busulfan overview